These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 20225291)

  • 1. Local institutional review board (IRB) review of a multicenter trial: local costs without local context.
    Ravina B; Deuel L; Siderowf A; Dorsey ER
    Ann Neurol; 2010 Feb; 67(2):258-60. PubMed ID: 20225291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Problematic variation in local institutional review of a multicenter genetic epidemiology study.
    McWilliams R; Hoover-Fong J; Hamosh A; Beck S; Beaty T; Cutting G
    JAMA; 2003 Jul; 290(3):360-6. PubMed ID: 12865377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transitioning to the National Institutes of Health single institutional review board model: Piloting the use of the Streamlined, Multi-site, Accelerated Resources for Trials IRB Reliance.
    Vardeny O; Hernandez AF; Cohen LW; Franklin A; Baqai M; Palmer S; Bierer BE; Cobb N
    Clin Trials; 2019 Jun; 16(3):290-296. PubMed ID: 30866676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of central institutional review boards for multicenter clinical trials in the United States: a review of the literature.
    Check DK; Weinfurt KP; Dombeck CB; Kramer JM; Flynn KE
    Clin Trials; 2013 Aug; 10(4):560-7. PubMed ID: 23666951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementing a Central IRB Model in a Multicenter Research Network.
    Burr JS; Johnson AR; Vasenina V; Bisping S; Coleman RW; Botkin JR; Dean JM
    Ethics Hum Res; 2019 May; 41(3):23-28. PubMed ID: 31108575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Institutional Review Board dilemma: responsible for safety monitoring but not in control.
    DeMets DL; Fost N; Powers M
    Clin Trials; 2006; 3(2):142-8. PubMed ID: 16773956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost of institutional review board procedures in multicenter observational research.
    Humphreys K; Trafton J; Wagner TH
    Ann Intern Med; 2003 Jul; 139(1):77. PubMed ID: 12834327
    [No Abstract]   [Full Text] [Related]  

  • 9. Approaches to facilitate institutional review board approval of multicenter research studies.
    Marsolo K
    Med Care; 2012 Jul; 50 Suppl():S77-81. PubMed ID: 22692264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of local institutional review board review on participation in national practice-based research network studies.
    Finch SA; Barkin SL; Wasserman RC; Dhepyasuwan N; Slora EJ; Sege RD
    Arch Pediatr Adolesc Med; 2009 Dec; 163(12):1130-4. PubMed ID: 19996050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variability of the institutional review board process within a national research network.
    Khan MA; Barratt MS; Krugman SD; Serwint JR; Dumont-Driscoll M;
    Clin Pediatr (Phila); 2014 Jun; 53(6):556-60. PubMed ID: 24658908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Institutional review board variability in minimal-risk multicenter urogynecology studies.
    Harvie HS; Lowenstein L; Omotosho TB; Sanses T; Molden S; Hardy J; Brubaker L;
    Female Pelvic Med Reconstr Surg; 2012; 18(2):89-92. PubMed ID: 22453318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time to institutional review board approval with local versus central review in a multicenter pragmatic trial.
    Neuman MD; Gaskins LJ; Ziolek T;
    Clin Trials; 2018 Feb; 15(1):107-111. PubMed ID: 28982261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Streamlining the institutional review board process in pragmatic randomized clinical trials: challenges and lessons learned from the Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) trial.
    Marquis-Gravel G; Robertson H; Jones WS; Riley D; Ford DE; Crenshaw D; Joosten YA; Rudov L; Hernandez AF; Hess R
    Trials; 2021 Jan; 22(1):90. PubMed ID: 33494785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variation in institutional review board responses to a standard, observational, pediatric research protocol.
    Mansbach J; Acholonu U; Clark S; Camargo CA
    Acad Emerg Med; 2007 Apr; 14(4):377-80. PubMed ID: 17312334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients come from populations and populations contain patients. A two-stage scientific and ethics review: The next adaptation for single institutional review boards.
    Knopman D; Alford E; Tate K; Long M; Khachaturian AS
    Alzheimers Dement; 2017 Aug; 13(8):940-946. PubMed ID: 28709585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ontario Cancer Research Ethics Board: lessons learned from developing a multicenter regional institutional review board.
    Saginur R; Dent SF; Schwartz L; Heslegrave R; Stacey S; Manzo J
    J Clin Oncol; 2008 Mar; 26(9):1479-82. PubMed ID: 18349399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [How to get an institutional review board (IRB) approval for clinical research].
    Letouzey V; Deffieux X
    Gynecol Obstet Fertil; 2010 Nov; 38(11):716-7. PubMed ID: 21030279
    [No Abstract]   [Full Text] [Related]  

  • 19. Central institutional review board review for an academic trial network.
    Kaufmann P; O'Rourke PP
    Acad Med; 2015 Mar; 90(3):321-3. PubMed ID: 25406606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variability in the costs of institutional review board oversight.
    Byrne MM; Speckman J; Getz K; Sugarman J
    Acad Med; 2006 Aug; 81(8):708-12. PubMed ID: 16868423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.